SA
Therapeutic Areas
Vertex Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Trikafta (elexacaftor/tezacaftor/ivacaftor) | Cystic Fibrosis | Approved |
| Kalydeco (ivacaftor) | Cystic Fibrosis | Approved |
| Orkambi (lumacaftor/ivacaftor) | Cystic Fibrosis | Approved |
| Symdeko (tezacaftor/ivacaftor) | Cystic Fibrosis | Approved |
| CTX001 | Sickle Cell Disease | Phase 3 |
| VX-548 | Acute Pain | Phase 3 |
| VX-150 | Painful Diabetic Peripheral Neuropathy | Phase 2 |
| VX-880 | Type 1 Diabetes | Phase 1/2 |
Leadership Team at Vertex Pharmaceuticals
RK
Reshma Kewalramani
Chief Executive Officer
CW
Charles Wagner
Chief Financial Officer
CB
Carmen Bozic
Chief Medical Officer
DA
David Altshuler
Chief Scientific Officer
BS
Bastiano Sanna
Chief of Cell and Genetic Therapies
JC
Jeffrey Chodakewitz
Chief Medical Officer, Non-CF
SB
Sangeeta Bhatia
Board Member
BD
Bruce Downey
Board Member
AG
Alan Garber
Board Member